MC38 HuSyngeneic Screen
ENROLLMENT OPEN NOW THROUGH November 30th
• B6 mice expressing human PD-1 & human CTLA4.
• MC38 cell line expressing human PD-L1.
MC38 huSyngeneic is a transgenic syngeneic platform which allows for the use of human therapeutics targeting PD-1, PD-L1 and/or CTLA4.
Participate in the Champions Oncology MC38 huSyngeneic screen for a more biologically relevant MC38 model.
Enrollment in this study is now open on a first-come-first-served basis.